KR102421006B1 - 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 - Google Patents

두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 Download PDF

Info

Publication number
KR102421006B1
KR102421006B1 KR1020170060706A KR20170060706A KR102421006B1 KR 102421006 B1 KR102421006 B1 KR 102421006B1 KR 1020170060706 A KR1020170060706 A KR 1020170060706A KR 20170060706 A KR20170060706 A KR 20170060706A KR 102421006 B1 KR102421006 B1 KR 102421006B1
Authority
KR
South Korea
Prior art keywords
formula
headache
migraine
pharmaceutical composition
carbamate compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020170060706A
Other languages
English (en)
Korean (ko)
Other versions
KR20170131240A (ko
Inventor
신혜원
박윤경
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Publication of KR20170131240A publication Critical patent/KR20170131240A/ko
Application granted granted Critical
Publication of KR102421006B1 publication Critical patent/KR102421006B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020170060706A 2016-05-19 2017-05-16 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 Active KR102421006B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160061374 2016-05-19
KR20160061374 2016-05-19

Publications (2)

Publication Number Publication Date
KR20170131240A KR20170131240A (ko) 2017-11-29
KR102421006B1 true KR102421006B1 (ko) 2022-07-14

Family

ID=60325338

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170060706A Active KR102421006B1 (ko) 2016-05-19 2017-05-16 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도

Country Status (8)

Country Link
US (2) US10456376B2 (enExample)
EP (1) EP3459541B1 (enExample)
JP (1) JP6986521B2 (enExample)
KR (1) KR102421006B1 (enExample)
CN (1) CN109310670B (enExample)
CA (1) CA3024278A1 (enExample)
ES (1) ES2893456T3 (enExample)
WO (1) WO2017200316A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323410A1 (en) 2009-06-22 2010-12-23 Sang Chul Lim Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US20110111467A1 (en) 2009-10-15 2011-05-12 Sang Chul Lim Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester
KR101286499B1 (ko) * 2005-04-22 2013-07-16 에스케이바이오팜 주식회사 신경치료용 아졸 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
US4349556A (en) * 1976-06-24 1982-09-14 Bayer Aktiengesellschaft Pesticidally active 1-acyloxy-1-phenyl-2-azolyl-ethanes
WO2003053916A1 (en) * 2001-12-21 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. Process for preparing 2-(substituted phenyl) - 2 - hydroxy-ethyl carbamates
PT1809273E (pt) * 2004-09-16 2010-05-10 Janssen Pharmaceutica Nv Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese
WO2011045380A1 (en) 2009-10-16 2011-04-21 Novartis Ag Apparatus and method for transporting contact lenses through dipping baths

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101286499B1 (ko) * 2005-04-22 2013-07-16 에스케이바이오팜 주식회사 신경치료용 아졸 화합물
US20100323410A1 (en) 2009-06-22 2010-12-23 Sang Chul Lim Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US20110111467A1 (en) 2009-10-15 2011-05-12 Sang Chul Lim Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Epilepsy Research, 92(2-3):89-124 (2010.12.01.)
European Journal of Medicinal Chemistry, 36(5):421-433 (2001)
NEUROLOGIC ASPECTS OF SYSTEMIC DISEASE PART I: "Chapter 33: Fibromyalgia", HANDBOOK OF CLINICAL NEUROLOGY, 119:513-527 (2014)
Novel Neurotherapeutic for Epilepsy, Neuropathic Pain and Bipolar Disorder, YKP3089 - SK biopharmaceuticals, <https://www.epilepsy.com/sites/core/files/atoms/files/6-6_S_James_Lee.pdf>(2012.12.31.)

Also Published As

Publication number Publication date
KR20170131240A (ko) 2017-11-29
US20200009113A1 (en) 2020-01-09
JP2019516726A (ja) 2019-06-20
EP3459541B1 (en) 2021-09-15
CN109310670A (zh) 2019-02-05
WO2017200316A1 (ko) 2017-11-23
US10456376B2 (en) 2019-10-29
ES2893456T3 (es) 2022-02-09
EP3459541A4 (en) 2020-01-08
JP6986521B2 (ja) 2021-12-22
US20190216780A1 (en) 2019-07-18
CN109310670B (zh) 2022-03-29
CA3024278A1 (en) 2017-11-23
EP3459541A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
US20200009113A1 (en) Use of carbamate compound in order to preventatively treat headaches
IL274431B1 (en) Use of a carbamate compound to reduce or treat developmental disorders including fragile X syndrome, Engelmann syndrome, or Rett syndrome
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
RU2751504C2 (ru) Применение карбамата для предупреждения или лечения невралгии тройничного нерва
KR102921943B1 (ko) 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
HK40003858B (en) Use of carbamate compound in order to preventatively treat headaches
HK40003858A (en) Use of carbamate compound in order to preventatively treat headaches
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5